TERT and central nervous system cancer: Thirty samples (13/16 ODGs, 17/26 GBMs) carried the c.-124C>T (TERT G228A) mutation and eight (three ODGs and five GBMs) the c.-146C>T (TERT G250A) mutation (Table 1), supporting the predominance of the G228A mutation in glioma [15].